Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria

A legfontosabb adatok

Ki végzi
GlaxoSmithKline
Hol
Gabon és Uganda2 helyszín, 2 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
70 fő, tervezett
Kezdés
2026. okt. 7.
Várható befejezés
2027. okt. 8.
A vizsgálat típusa
Beavatkozással járó, 5 csoport
A vizsgált kezelések
  • GSK3772701 600 mg
  • GSK3772701 900 mg
  • GSK3772701 150 mg
  • GSK3772701 400 mg
  • GSK3772701 50 mg
A regiszteradat frissítve
2026. november 10.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Male and female patients aged 18 to 65 years
  • Presence of malaria due to mono-infection with P. falciparum confirmed by:; Fever, as defined by axillary temperature >=37.5°C or oral/tympanic temperature >=38°C and,; Microscopically confirmed P. falciparum malaria parasite mono-infection,; A parasite count between 2,000 to 60,000 asexual parasite count/µL of blood for P. falciparum
  • Have a BMI between >=18 and <=30 kg/m2
  • Able to swallow oral medication
  • Signed informed consent, acknowledging understanding and willingness to comply with the requirements of the study. If the patient is unable to write, thumb print consent, signed by an impartial witness is permitted according to local ethical considerations
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:; Is a woman of non-childbearing potential (WONCBP) or; Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method, from Study Day 1, and during the study intervention period (40 +/-3 days)

Ki nem vehet részt

  • Significant illness within two weeks prior to screening
  • Known history or evidence (based on clinical examination or investigation) of uncontrolled active cardiovascular disease (including hypertension), respiratory disease (including active tuberculosis even if treatment is ongoing), liver cirrhosis or liver disease (based on prior investigation, clinical signs and/or interpretation of liver enzymes), other active hepatic, renal, gastrointestinal, immunological, neurological, endocrine, infectious, or psychiatric disease
  • Have received any antimalarial treatment in the preceding 6 weeks (see Section 6.10), as determined by history or medical record
  • Prior enrolment in this study and receipt of treatment with GSK3772701
  • Use of other investigational drugs at the time of enrolment, or within 6 weeks, or 5 half-lives prior to enrolment into this study, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations
  • History of drug or alcohol abuse within 3 months prior to dosing, or clinical evidence of such abuse
  • Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention; Note: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention; Note: Test is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing
  • Mixed Plasmodium infection, i.e., infection with more than one malaria (plasmodium) species (by microscopy; participant to be withdrawn from study treatment if PCR subsequently indicates presence of mixed infection)
  • History of malignancy (or current malignancy) of any organ system (other than localized carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
  • Positive HIV antibody test at screening, or history of HIV infection based on past positive test result, clinical record or current treatment
  • Anaemia (Hb <=8.0g/dl) or known clinically important chronic underlying haematological disease such as sickle cell disease at screening
  • Significant chronic medical conditions which in the opinion of the investigator preclude enrolment into the study
  • History of hypersensitivity to the study drug or drug formulation and capsule (Hypromellose (hydroxypropyl methylcellulose)) constituents
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Any clinically significant ECG abnormalities at Screening unrelated to malaria (including but not limited to, second degree AV block (Mobitz Type 2), complete heart block, ST changes, atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, prolonged QT interval
  • Creatinine >=2 x ULN
  • ALT >2.0 x ULN
  • Total bilirubin >1.5 x ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is <=1.5xULN
  • Patients with signs and symptoms of severe/complicated malaria according to the WHO 2024 Criteria
  • Abnormal values: QTcF >450 msec or QTcF >480 msec for patients with bundle branch block
  • Severe vomiting, defined as more than 3 times in the 24 hours before screening or inability to tolerate oral treatment
  • Severe diarrhoea defined as more than 3 watery stools per day in the 24 hours before screening
  • Participants who in the opinion of the Investigator are unsuitable for participation in the study or cannot be enrolled due to logistical reasons

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Gabon és Uganda.

2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.

A vizsgálat 5 csoportja

  • Cohort 1_Single DoseA vizsgált kezelés

    Participants receive a single GSK3772701 600 mg dose on Day 1.

    Kezelés: GSK3772701 600 mg

  • Cohort 2_ Single DoseA vizsgált kezelés

    Participants receive a single GSK3772701 900 mg dose on Day 1.

    Kezelés: GSK3772701 900 mg

  • Cohort 3_ Repeat DoseA vizsgált kezelés

    Participants receive a daily 150 mg dose of GSK3772701 on Day 1 and Day 2.

    Kezelés: GSK3772701 150 mg

  • Cohort 4_ Repeat DoseA vizsgált kezelés

    Participants receive a daily 400 mg dose of GSK3772701 on Day 1 and Day 2.

    Kezelés: GSK3772701 400 mg

  • Cohort 5_ Repeat DoseA vizsgált kezelés

    Participants receive a daily 50 mg dose of GSK3772701 on Day 1, Day 2 and Day 3.

    Kezelés: GSK3772701 50 mg

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 2A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Antimalarial Pyrrolidinamide at Different Doses and Dose Durations, in Adult Patients With Uncomplicated P. Falciparum Malaria
Kérdések a feltételekről
Forrás: NCT07545681: ki vehet részt
A regiszteradat frissítve
2026. november 10.